[Predictors of response to biologic therapies in rheumatoid arthritis].

Autor:	Chaves Chaparro LM; Servicio de Reumatología, Hospital Clínico San Cecilio, Granada, España. lara chch@hotmail.com, Salvatierra Ossorio J, Raya Álvarez E
Jazyk:	Spanish; Castilian
Zdroj:	Reumatologia clinica [Reumatol Clin] 2011 Mar-Apr; Vol. 7 (2), pp. 141-4. Date of Electronic Publication: 2011 Feb 24.
DOI:	10.1016/j.reuma.2010.11.004
Abstrakt:	The advent of biological therapies has revolutionized the management of rheumatoid arthritis, demonstrating effectiveness in controlling clinical and radiological damage. However, 20 to 40% of the patients will not respond to these therapies, which are associated to a very high cost. In addition, non-responder patients are exposed to possible adverse effects. For these reasons, we need to identify predictors of response to these treatments. These predictors are reviewed in this evidence-based paper and classified into genetic and non-genetic. Despite extensive search, nowadays there are no predictors powerful enough to be used in regular clinical practice. Serum factors, the presence of rheumatoid factor and anti-cyclic citrullinated peptide antibodies, are the only factors currently being used to predict the response to specific biological therapy. In the future, probably thanks to new technologies based on genomics, transcriptomics and proteomics, it will be possible to identify genetic predictors of response to biological drugs that will allow us to select suitable patients for a specific biological therapy. (Copyright © 2010 Elsevier España, S.L. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu